Nureca Ltd. AI Stock Analysis
Want to see IN:NURECA full AI Analyst Report?
Nureca Ltd. (NURECA) AI Stock Analysis
Nureca Ltd.
(NSE:NURECA)
The overall score of 58 reflects a company in the early stages of a financial turnaround, supported by a very strong balance sheet. The primary positive driver is the bullish technical momentum, indicating market confidence in the recovery. However, this is significantly offset by an extremely high valuation (P/E of 88.5) and the company's currently thin profitability and fragile cash flows, which present substantial risk if the growth trajectory falters.
Nureca Ltd. (NURECA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 2.97B
- Dividend Yield
- ―
- Average Volume (3M)
- 858
- Price to Earnings (P/E)
- 62.7
- Beta (1Y)
- 0.82
- Revenue Growth
- 33.66%
- EPS Growth
- 17.10%
- Country
- India
- Employees
- 154
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Nureca Ltd. Business Overview & Revenue Model
Company Description
Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic conditio...
Nureca Ltd. Financial Statement Overview
Summary
Nureca is showing a recovery with two years of revenue growth and a return to profitability. However, net margins remain very thin at 1.4% and cash flow, while improved, is still fragile. The strong, debt-light balance sheet is a major positive, but overall financial health is tempered by low profitability and historically volatile cash generation.
Income Statement
48NeutralBalance Sheet
82Very PositiveCash Flow
42Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.74B | 1.47B | 1.10B | 919.28M | 1.11B | 2.56B |
| Gross Profit | 444.82M | 352.34M | 231.33M | 311.42M | 355.94M | 1.23B |
| EBITDA | 111.18M | 85.19M | 48.95M | 2.41M | -79.04M | 632.04M |
| Net Income | 47.60M | 20.82M | 8.46M | -17.94M | -82.50M | 449.60M |
Balance Sheet | ||||||
| Total Assets | 2.31B | 1.96B | 2.10B | 2.05B | 2.07B | 2.19B |
| Cash, Cash Equivalents and Short-Term Investments | 735.52M | 424.31M | 736.29M | 1.44B | 1.02B | 927.10M |
| Total Debt | 66.01M | 22.59M | 49.66M | 25.16M | 33.27M | 44.05M |
| Total Liabilities | 433.97M | 153.96M | 156.91M | 120.54M | 116.97M | 159.32M |
| Stockholders Equity | 1.88B | 1.81B | 1.94B | 1.93B | 1.95B | 2.03B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 17.45M | -234.06M | -37.98M | 98.31M | -46.00M |
| Operating Cash Flow | 0 | 85.74M | -190.83M | -27.12M | 102.27M | 13.99M |
| Investing Cash Flow | 0 | 81.20M | 84.39M | 175.76M | -164.56M | -30.89M |
| Financing Cash Flow | 0 | -184.66M | -1.69M | -13.03M | -15.07M | -73.02M |
Nureca Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Negative. The current price of 297.05 is below the 20-day moving average (MA) of 309.62, below the 50-day MA of 326.00, and above the 200-day MA of 286.52, indicating a neutral trend. The MACD of -7.42 indicates Positive momentum. The RSI at 38.28 is Neutral, neither overbought nor oversold. The STOCH value of 48.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NURECA.
Nureca Ltd. Peers Comparison
Overall Rating
IN:BLUEJET71Outperform
IN:PGHL64Neutral
IN:AMRUTANJAN62Neutral
IN:NURECA58Neutral
IN:ZOTA45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | INR 96.53B | 31.91 | ― | 0.23% | -7.05% | -21.25% | |
| 64Neutral | INR 90.83B | 23.88 | ― | 3.86% | 13.04% | 4.60% | |
| 62Neutral | INR 14.87B | 25.64 | ― | 0.96% | 10.68% | -1.04% | |
| 58Neutral | INR 2.83B | 62.69 | ― | ― | 33.66% | 17.10% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 45Neutral | INR 39.15B | -38.48 | ― | 0.08% | 68.95% | -55.82% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:NURECA | Nureca Ltd. | 297.05 | 34.05 | 12.95% | |
| IN:AMRUTANJAN | Amrutanjan Health Care Limited | 508.75 | -187.17 | -26.90% | |
| IN:BLUEJET | Blue Jet Healthcare Limited | 510.00 | -57.96 | -10.21% | |
| IN:PGHL | Procter & Gamble Health Ltd. | 5472.05 | -189.38 | -3.35% | |
| IN:SANOFICONR | Sanofi Consumer Healthcare India Limited | 3525.95 | -1095.86 | -23.71% | |
| IN:ZOTA | Zota Health Care Ltd. | 1290.60 | -356.56 | -21.65% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 29, 2026
